Stock Watch: The Competition Has It
An Existing Standard Of Care Provides A High Barrier To Late-Comers
Executive Summary
Apart from assuming that its new drug will always be a blockbuster, the other common mistake made by biotech companies and investors is that there will invariably be a viable market for its drug. The competition will have other ideas.
You may also be interested in...
Stock Watch: Amarin And Esperion Cut Sales And Marketing Costs
Unlike big pharma, some small commercial companies cut sales and marketing costs in 2021. But with a little imagination, it could go further.
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.
Stock Watch: Orphan Drug Profitability Under Threat
The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?